Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

Company Overview

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $1.07 to $1.22
• 50-Day Range: $1.05 to $4.17
• 52-Week Range: $1.03 to $13.14
• Volume: 61,782 shs
• Average Volume: 34,770 shs
• Market Capitalization: $3.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Hold

Oncternal Therapeutics Stock Analysis - MarketRank™

Oncternal Therapeutics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Oncternal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oncternal Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncternal Therapeutics are expected to grow in the coming year, from ($12.43) to ($10.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncternal Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncternal Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oncternal Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.71% of the float of Oncternal Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oncternal Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncternal Therapeutics has recently increased by 168.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncternal Therapeutics does not currently pay a dividend.

Dividend Growth

Oncternal Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.71% of the float of Oncternal Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oncternal Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncternal Therapeutics has recently increased by 168.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.49

News Sentiment

Oncternal Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Oncternal Therapeutics this week, compared to 1 article on an average week.

Search Interest

6 people have searched for ONCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncternal Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.20% of the stock of Oncternal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.05% of the stock of Oncternal Therapeutics is held by institutions.

ONCT Stock Analysis - Frequently Asked Questions

How have ONCT shares performed this year?

Oncternal Therapeutics' stock was trading at $10.7240 at the beginning of the year. Since then, ONCT stock has decreased by 89.4% and is now trading at $1.14.
View the best growth stocks for 2024 here.

How were Oncternal Therapeutics' earnings last quarter?

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($2.89) EPS for the quarter, beating analysts' consensus estimates of ($3.03) by $0.14. The company earned $0.80 million during the quarter, compared to the consensus estimate of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,599.95% and a negative trailing twelve-month return on equity of 177.58%.

When did Oncternal Therapeutics' stock split?

Shares of Oncternal Therapeutics reverse split on the morning of Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Oncternal Therapeutics?

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Oncternal Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include Palantir Technologies (PLTR), NIO (NIO), Walt Disney (DIS), Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/16/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONCT
• CUSIP: N/A
• CIK: 1260990
• Web: www.oncternal.com
• Phone: (858) 434-1113
• Fax: 901-844-8075
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.00
• High Stock Price Target: $40.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +1,654.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($11.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-39,480,000.00
• Net Margins: -1,599.95%
• Pretax Margin: -1,599.95%
• Return on Equity: -177.58%
• Return on Assets: -131.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.39
• Quick Ratio: 2.39

Sales & Book Value

• Annual Sales: $790,000.00
• Price / Sales: 4.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.09 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 2,960,000
• Free Float: 2,628,000
• Market Cap: $3.37 million
• Optionable: No Data
• Beta: 1.33